This HTML5 document contains 93 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
wdt	http://www.wikidata.org/prop/direct/
wdtn	http://www.wikidata.org/prop/direct-normalized/
schema	http://schema.org/
rdfs	http://www.w3.org/2000/01/rdf-schema#
skos	http://www.w3.org/2004/02/skos/core#
wikibase	http://wikiba.se/ontology#
p	http://www.wikidata.org/prop/
n10	http://dx.doi.org/10.1200/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n12	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdh	http://www.w3.org/2001/XMLSchema#
wds	http://www.wikidata.org/entity/statement/
wd	http://www.wikidata.org/entity/

Statements

Subject Item

wd:Q37777290

rdf:type

wikibase:Item

schema:description

научни чланак bilimsel makale scientific article published on 02 August 2010 articolo scientifico vedecký článok wetenschappelijk artikel videnskabelig artikel artigo científico vetenskaplig artikel artículu científicu espublizáu en 2010 article scientifique article científic wissenschaftlicher Artikel vědecký článek مقالة علمية نشرت في 02 أغسطس 2010 наукова стаття, опублікована в серпні 2010

p:P577

wds:Q37777290-12F0EDF3-7D98-4128-A82A-B74A6444134F

wdt:P577

2010-08-02T00:00:00Z

p:P407

wds:Q37777290-4E6DE2AB-4951-48DE-8327-68326257943F

wdt:P407

wd:Q1860

p:P2093

wds:Q37777290-EC3A6F68-4342-403D-BE47-C1A63E0BCF8B wds:Q37777290-1D251ED4-926F-46D2-BEFF-3FE1C15E4159 wds:Q37777290-2FFCCB1F-7CAE-4F63-9F4B-40E2000C001B wds:Q37777290-3F28A755-14FE-4527-B587-C43EF57485CC wds:Q37777290-5D97B948-F0D4-417B-991A-FA886938B05C wds:Q37777290-6337D54E-6EE1-4A7B-960E-AD222ACDA8AB wds:Q37777290-64B9C332-49CA-4979-9ED5-68C4EE80B5E8 wds:Q37777290-6C2C14FB-0A7E-4DA1-A757-3B0D4E4DABFD wds:Q37777290-8859FECA-FA0E-4C7F-9E4F-2ACBB156BFE5 wds:Q37777290-7E344198-6810-4744-B81E-2F9A4AC9DE80 wds:Q37777290-81C84783-0F74-48DC-B79A-8135DCB693B6 wds:Q37777290-9765DB3D-12CC-4446-8A2C-B62EEF1A86B0 wds:Q37777290-E343AC20-F54B-4685-B566-D2F0FE0F8498

wdt:P2093

Renuka Gurnani Ahmad Awada Anthony Goncalves Simon Ashworth Elaine Richmond Henri Roché Mario Campone Fang Fang Dale E Shuster Jantien Wanders Robert Paridaens Patricia E Cole Mary Ann Allison

rdfs:label

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

skos:prefLabel

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

schema:name

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

p:P50

wds:Q37777290-ADBDFD61-9718-4794-8EE2-E68B75C6EB48 wds:Q37777290-D016B826-96E7-47BC-A529-A6F93FDC34F7 wds:Q37777290-6E8EB244-2068-4230-94A1-010303B9A611 wds:Q37777290-4FCD9FBB-014A-469A-94C6-C46302A07228 wds:Q37777290-12EC339A-8ADA-47CA-B7BC-64AF5EA9D7E4

wdt:P50

wd:Q40149511 wd:Q92433588 wd:Q43114235 wd:Q47067174 wd:Q89504757

p:P1476

wds:Q37777290-275FD8B1-5611-4496-B8B1-83DF37B853EB

wdt:P1476

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

p:P304

wds:Q37777290-F71D2D7D-966D-4313-B6DC-CB644ADE82D5

wdt:P304

3922-3928

p:P31

wds:Q37777290-5CBBB87E-9E13-4032-B5B3-9A900F92F11F

wdt:P31

wd:Q13442814

p:P921

wds:Q37777290-58B12651-D748-4DCA-AEB6-825659C8DCD7 wds:Q37777290-79039890-16E8-40D4-AF0C-C47463F0364C

wdt:P921

wd:Q181600 wd:Q12859063

p:P698

wds:Q37777290-FABC26DD-17C8-41C2-95E9-5944FB623376

wdtn:P698

n12:20679609

wdt:P698

20679609

p:P1433

wds:Q37777290-8DBF4C23-9ED2-4F60-B557-5808012F8E6E

wdt:P1433

wd:Q400292

p:P433

wds:Q37777290-27E2B2DD-8C5C-4C69-BADF-AFBD0C78F1B5

p:P478

wds:Q37777290-8C886100-40CC-4A8A-A895-1AADB2E8811A

wdt:P433

25

wdt:P478

28

p:P356

wds:Q37777290-CD5D46E2-4626-482A-9646-6CD296150D46

wdtn:P356

n10:JCO.2009.25.8467

wdt:P356

10.1200/JCO.2009.25.8467

p:P5875

wds:Q37777290-C4C0EA55-7D41-48DA-B750-C7370C79C1C7

wdt:P5875

45461748